05 February 2024
05 February 2024
AbbVie’s Tepkinly has been recommended for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
Bristol Myers Squibb (BMS) has reported a 2% revenue decrease from 2022 as it focuses on business development to counteract patent losses.
The company reported a significant decline in earnings per share for the full year 2023.
England evaluates vaccine procurement and pandemic preparedness while Moderna’s mRNA vaccine creeps closer to regulatory approval.
The latest submission is based on findings from the Phase I/II LINKER-MM1 trial of linvoseltamab in relapsed/refractory (r/r) multiple myeloma (MM) patients.
The MAA submission is based on results from the randomised, international Phase III innovaTV 301 trial.
HUTCHMED is entitled to receive $92.5m in development milestone payments under the deal.
With TGR-63 advancing towards the clinical stage, IGC Pharma is tackling different small molecule alternatives to treat Alzheimer’s.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
